Please assess the completion status of the following clinical trial:

Trial Title: APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Male or female patients, aged ≥ 18.~2. Willing and able to give written, informed consent.~3. Confirmed diagnosis of MM.~4. Measurable disease as defined by IMWG.~5. Relapse or refractory disease and have had at least 3 different prior lines of therapy including proteasome inhibitor, alkylator and immunomodulatory therapy (IMiD), or have double refractory disease to a proteasome inhibitor and IMiD.~6. For females of childbearing potential, a negative serum or urine pregnancy test must be documented at screening and confirmed before receiving study treatment.~7. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1.~8. Peripheral blood total lymphocyte count \> 0.5 x 10⁹/L.~Key Exclusion Criteria:~1. Women who are pregnant or lactating.~2. Prior treatment with investigational or approved gene therapy or cell therapy products.~3. Patient has previously received an allogenic stem cell transplant.~4. Clinically significant, uncontrolled heart disease or a recent (within 6 months) cardiac event.~5. Left Ventricular Ejection fraction \< 50 unless the institutional lower limit of normal is lower.~6. Significant liver disease: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3 × ULN, or total bilirubin \> 2.0 mg/dL or evidence of end stage liver disease (e.g. ascites, hepatic encephalopathy).~7. Chronic renal impairment requiring dialysis, or calculated creatinine clearance \< 30 mL/min~8. Active infectious bacterial or viral disease (hepatitis B virus, hepatitis C virus, human immunodeficiency virus, human T-lymphotropic virus or syphilis) requiring treatmenUse of rituximab within the last 3 months.~9. Active autoimmune disease requiring immunosuppression.~10. Received any anti-myeloma therapy within the last 21 days prior to preconditioning or 10 days prior to leukapheresis; steroids of up to 160 mg of dexamethasone are permitted so long as \> 7 days post-dose prior to pre-conditioning or leukapheresis.~11. Known allergy to albumin, dimethyl sulfoxide (DMSO), cyclophosphamide or fludarabine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AUTO2 (Type: EXPERIMENTAL): Relapsed or refractory Myeloma patients

Based on this trial design, predict the completion outcome and termination type (if applicable).